Search results for: The Netherlands
Filter search results
Around The World in HTAs: The Netherlands – 5 Routes for New Tech
24 May 2023
…of pharmaceuticals in the Netherlands There are two assessment procedures for outpatient pharmaceuticals in the Netherlands: Procedures to allow entry onto the Dutch market: these procedures take place via the…
Looking Further Afield – What Can Health Economics Learn from the Environmental Economics Approach to Discounting?
1 February 2024
…future costs and benefits less than those that occur now. The further into the future costs and effects fall, the less they are valued through the impact of discount rate…
The broader economic benefits of COVID-19 vaccination
13 October 2025
…groups protects healthcare systems but leaves national economies exposed to the impact of COVID-19 Annual autumn COVID-19 vaccination of older adults (aged 60+ in the Netherlands and 65+ in the…
Reflections from Adrian Towse on decades of HEOR research and impact
11 November 2025
…the example of the Meningococcal C vaccine purchase by the UK Department ofHealth writing the Briefing Paper for UK DIFD with Nobel Prize winner Michael Kremer. The UK funded the…
Navigating the Intersection of Healthcare and Environmental Sustainability: ISPOR Europe round-up on the inclusion of environmental impact in HTA
17 January 2024
…mission and tasks of the organisation and manage their internal emissions. In planning how they could incorporate environmental impact on the products assessed via HTA, they proposed a four-step growth…
Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?
4 January 2024
…there could be enormous variability in the value of the TEV depending on the sales value of the products reaching the end of their patent life or data exclusivity period….
A Market-based International Reference Price Index: Solution or Contradiction?
13 September 2019
…in particular, the relative market orientation of their health care systems and therefore, broadly speaking, their preferences for health. Roy argues that these four countries are “the most market-oriented health…
New OHE model estimates COVID-19 could be associated with costs of £7 billion a year in the UK, without annual autumn vaccinations
13 October 2025
…https://www.ohe.org/publications/the-broader-economic-benefits-of-covid-19-vaccination/. The report was commissioned and funded by Moderna. OHE conducted the analysis and drafted the report. Cost of illness analyses evaluate the economic impact associated with the morbidity and…
Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?
15 February 2023
…the discount rate for costs under opportunity 2. All three opportunities can potentially address the challenges posed by gene therapies, but their success will depend on the quality of the…